American Journal of Therapeutics | 2021
Cutaneous Immune-Related Adverse Events in Anti-Protein 1 Pathway Therapy: A Case Series and Literature Review.
Abstract
The development of immune checkpoint inhibitors has led to a paradigm shift in the way several malignancies are managed. Immune checkpoint inhibitors directed at the programmed cell death protein 1 pathway (PD1), including nivolumab and durvalumab, have been approved for the treatment of multiple cancers. Unfortunately, as with any therapy, immunotherapy has side effects from misdirected stimulation of the immune system on normal tissue. Here, we present 2 cases of anti-PD-1 therapy induced cutaneous adverse effects.